tetano
Editor, Senior Moderator
Virology. 2018 Sep 21;525:73-82. doi: 10.1016/j.virol.2018.09.007. [Epub ahead of print]
[h=1]Combined use of live-attenuated and inactivated influenza vaccines to enhance heterosubtypic protection.[/h] Yan LM[SUP]1[/SUP], Li OTW[SUP]1[/SUP], Poh CM[SUP]1[/SUP], Perera RAPM[SUP]1[/SUP], Valkenburg SA[SUP]2[/SUP], Peiris M[SUP]1[/SUP], Poon LLM[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The limited protection of current commerical vaccines necessitates the investigation of novel vaccine strategies for unpredictable outbreaks. To investigate the feasibility of using vaccines derived from Group 1 influenza A virus to induce broadly cross-reactive immune responses against multiple influenza subtypes, we tested a panel of sequential 4-dose immunization regimens in mice. Mice were treated with inactivated (seasonal H1N1, pandemic H1N1 and H5N1) and vaccinia virus-based H5N1 live-attenuated vaccines in different combinations. Mice were then challenged by viruses of either Group 1 (H1N1) or Group 2 (H3N2, H7N7) influenza virus. All studied sequential 4-dose vaccinations could induce some degrees of heterosubtypic protection in mice. Amongst all these regimens, the combined use of inactivated and live-attenuated vaccines could achieve the best heterologous protection. These results highlight the synergistic effect of combining different vaccine platforms to enhance heterosubtypic protection against influenza viruses.
[h=4]KEYWORDS:[/h] Heterosubtypic immunity; Influenza; Universal vaccine
PMID: 30248524 DOI: 10.1016/j.virol.2018.09.007
[h=1]Combined use of live-attenuated and inactivated influenza vaccines to enhance heterosubtypic protection.[/h] Yan LM[SUP]1[/SUP], Li OTW[SUP]1[/SUP], Poh CM[SUP]1[/SUP], Perera RAPM[SUP]1[/SUP], Valkenburg SA[SUP]2[/SUP], Peiris M[SUP]1[/SUP], Poon LLM[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The limited protection of current commerical vaccines necessitates the investigation of novel vaccine strategies for unpredictable outbreaks. To investigate the feasibility of using vaccines derived from Group 1 influenza A virus to induce broadly cross-reactive immune responses against multiple influenza subtypes, we tested a panel of sequential 4-dose immunization regimens in mice. Mice were treated with inactivated (seasonal H1N1, pandemic H1N1 and H5N1) and vaccinia virus-based H5N1 live-attenuated vaccines in different combinations. Mice were then challenged by viruses of either Group 1 (H1N1) or Group 2 (H3N2, H7N7) influenza virus. All studied sequential 4-dose vaccinations could induce some degrees of heterosubtypic protection in mice. Amongst all these regimens, the combined use of inactivated and live-attenuated vaccines could achieve the best heterologous protection. These results highlight the synergistic effect of combining different vaccine platforms to enhance heterosubtypic protection against influenza viruses.
[h=4]KEYWORDS:[/h] Heterosubtypic immunity; Influenza; Universal vaccine
PMID: 30248524 DOI: 10.1016/j.virol.2018.09.007